| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
5 companies
Lynx1 Capital Management LP is a 10% Owner at CGEM with holdings across 5 companies. Recent SEC Form 4 filings include 6 buys and 3 sells.
Estimated insider holdings value: $168.7M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 13, 2024 | TCRX Tscan Therapeutics, Inc. | 10% Owner | Buy | 131,800 | $2.93 | $385,768.96 | +1.3% | -37.2% | -64.6% | |
| Nov 27, 2024 | PASG Passage Bio, Inc. | 10% Owner | Buy | 456,353 | $0.62 | $284,519.51 | +1.8% | -20.9% | -33.8% | |
| Nov 15, 2024 | TCRX Tscan Therapeutics, Inc. | 10% Owner | Buy | 947 | $4.34 | $4,113.96 | - | -53.7% | -75.1% | |
| May 31, 2023 | TCRX Tscan Therapeutics, Inc. | 10% Owner | Sell | 25,400 | $2.52 | $63,952.50 | -0.2% | +5.7% | +260.4% |